SEC Company Response from Armata Pharmaceuticals, Inc. (ARMP) (CIK 0000921114) (ARMP) — Feb 8, 2007
Armata Pharmaceuticals, Inc. (ARMP) (CIK 0000921114)
Date: Feb. 8, 2007 · CIK: 0000921114 · Accession: 0001144204-07-005865
AI Filing Summary & Sentiment
File numbers found in text: 333-140187
Show Raw Text
CORRESP
1
filename1.htm
[Letterhead
of Targeted Genetics Corporation]
February
8, 2007
VIA
FACSIMILE (202-772-9217) AND EDGAR
Mr.
Jeffrey P. Riedler
Assistant
Director
Division
of Corporation Finance
Securities
and Exchange Commission
100
F
Street, NE
Washington,
DC 20549
Attention:
Song P. Brandon, Esq.
Re:
Targeted
Genetics Corporation - Request for Acceleration of
Effectiveness
of Registration Statement on Form S-3, Commission File
No.
333-140187
Dear
Mr.
Riedler,
Pursuant
to Rule 461 of the General Rules and Regulations under the Securities Act of
1933, as amended, Targeted Genetics Corporation (the “Company”)
hereby
requests that the effective
date of its Registration Statement on Form S-3, Registration No. 333-140187
(the
“Registration
Statement”)
be
accelerated so that the Registration Statement may become effective at the
later
of: (a) 4:00 p.m., Eastern Standard Time, Thursday, February 8, 2007, or as
soon
as practicable thereafter; and (b) such later time as the Company may request
by
telephone to the Commission. The Company hereby authorizes Stephen M. Graham
or
Lewis S. Malakoff of Orrick, Herrington & Sutcliffe LLP, counsel for the
Company, to make such a request on its behalf.
Very
truly yours,
TARGETED GENETICS
CORPORATION
/s/ David
J.
Poston
David J. Poston
Vice
President Finance and
Chief Financial
Officer
cc:
Orrick,
Herrington & Sutcliffe LLP